DiaMedica Therapeutics (NASDAQ:DMAC – Free Report) had its target price trimmed by Craig Hallum from $11.00 to $8.00 in a research note published on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. Separately, Oppenheimer reiterated an outperform rating and issued a $6.00 price objective (down previously from $7.00) on […]